SCHEMBL111042

SCHEMBL111042

CCCCCCCCCCCCCOC(=O)c1ccc(C(=O)OCCCCCCCCCCCCC)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.83
▸ NPC1 O15118 1/20 0.83
▸ MAPT P10636 1/20 0.83
▸ RAB9A P51151 1/20 0.83
▸ TSHR P16473 4/20 0.73
▸ ESR1 P03372 4/20 0.73
▸ LMNA P02545 3/20 0.73
▸ CYP1A2 P05177 2/20 0.73
▸ CYP2C19 P33261 2/20 0.73
▸ MAPK1 P28482 2/20 0.73
▸ CYP2D6 P10635 1/20 0.73
▸ NR1H2 P55055 1/20 0.73
▸ RNASEL Q05823 1/20 0.73
▸ SMN1; SMN2 Q16637 1/20 0.73
▸ CYP3A4 P08684 2/20 0.71
▸ CYP2C9 P11712 1/20 0.71
▸ PDE4D Q08499 1/20 0.71
▸ STS P08842 6/20 0.69
▸ AKR1C4 P17516 1/20 0.67
▸ AKR1C3 P42330 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9355410 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL17982649 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL17984533 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL17982629 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL9244915 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL21048393 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL2867627 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL108213 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL43953 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR
SCHEMBL10332518 1.00 ALDH1A1 (0.83) ALDH1A1NPC1MAPTRAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108407325-B Glass fiber composite material plate forming equipment and method 重庆国际复合材料股份有限公司 2020-12-11 — — CN claimed
EP-1567470-B1 HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF EXXONMOBIL CHEM PATENTS INC (US) 2013-06-05 — — EP claimed
US-7875742-B2 hydrogenating organic compounds by contacting with hydrogen-containing gas in presence of catalyst which comprises catalytically active metals applied to porous catalyst support; catalytically active metals having been derived via decomposed amine complex of metal on support EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-01-25 — — US claimed
US-20100184895-A1 Hydrogenation Processes EXXONMOBOIL RESEARCH AND ENGINEERING COMPANY 2010-07-22 — — US claimed
US-7595420-B2 Hydrogenation of benzene polycarboxylic acids or derivatives thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2009-09-29 — — US claimed
US-20060247461-A1 Hydrogenation of benzene polycarboxylic acids or derivatives thereof EXXONMOBIL CHEMICAL PATENTS INC. 2006-11-02 — — US claimed
EP-1567470-A1 HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF ExxonMobil Chemical Patents Inc. (US) 2005-08-31 — — EP claimed
WO-2004046078-A1 HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-06-03 — — WO claimed
US-20250230121-A1 TEMPERATURE CONTROL IN THE PREPARATION OF ALICYCLIC POLYCARBOXYLIC ACIDS AND ESTERS THEREOF EVONIK OXENO GMBH & CO. KG (DE) 2025-07-17 — — US disclosed
US-20250230122-A1 TEMPERATURE CONTROL IN THE PREPARATION OF ALICYCLIC POLYCARBOXYLIC ACIDS AND ESTERS THEREOF EVONIK OXENO GMBH & CO. KG (DE) 2025-07-17 — — US disclosed
EP-4574810-A1 STATIC MIXERS IN THE PRODUCTION OF ALICYCLIC CARBOXYLIC ACIDS AND THEIR ESTERS Evonik Oxeno GmbH & Co. KG (DE) 2025-06-25 — — EP disclosed
US-20250197320-A1 STATIC MIXERS IN THE PREPARATION OF ALICYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF EVONIK OXENO GMBH & CO. KG (DE) 2025-06-19 — — US disclosed
US-20250179243-A1 MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM TOSOH CORPORATION (JP) 2025-06-05 — — US disclosed
EP-3228667-B1 INSULATION MATERIAL KURARAY CO (JP) 2025-02-05 — — EP disclosed
EP-1578712-A2 HYDROGENATION CATALYST, PREPARATION THEREOF AND HYDROGENATION PROCESSES USING THIS CATALYST ExxonMobil Research and Engineering Company (US) 2005-09-28 — — EP disclosed
EP-1567470-A1 HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF ExxonMobil Chemical Patents Inc. (US) 2005-08-31 — — EP disclosed
US-20050038285-A1 Alicyclic polycarboxylic ester mixtures with a high trans proportion and method for the production thereof OXENO OLEFINCHEMIE GMBH (DE) 2005-02-17 — — US disclosed
US-20040260113-A1 Mixture of alicyclic polycarboxylic esters with high cis content EVONIK DEGUSSA GMBH (DE) 2004-12-23 — — US disclosed
WO-2004046076-A2 HYDROGENATION CATALYST, PREPARATION THEREOF AND HYDROGENATION PROCESSES USING THIS CATALYST EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2004-06-03 — — WO disclosed
WO-2004046078-A1 HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184895-A1 Hydrogenation Processes HAO2, HVCN1, AOC3 ALDH1A1 1483/4885NPC1 3101/4885MAPT 3739/4885
US-20250179243-A1 MAIN CHAIN POLYMER, OPTICAL FILM, METHOD FOR PRODUCING MAIN CHAIN POLYMER, METHOD FOR PRODUCING OPTICAL FILM, AND MULTILAYER FILM C9, RNF4, F12 ALDH1A1 885/4885NPC1 2990/4885MAPT 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback